

Addendum

Addendum: Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival**Mark B. Ulanja¹, Alastair E. Moody², Bryce D. Beutler³, Daniel Antwi-Amoabeng¹, Ganiyu A. Rahman⁴ and Olatunji B. Alese⁵**¹Christus Ochsner Saint Patrick Hospital, Lake Charles, LA 70601, USA²Department of Anesthesiology, University of Utah, Salt Lake City, UT 84112, USA³Department of Radiology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA⁴Department of Surgery, University of Cape Coast, School of Medical Sciences, Cape Coast, Ghana⁵Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA**Published:****Copyright:** © 2023 Ulanja et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** No funding was used for this publication.Original article: Oncotarget. 2022; 13:828–841. <https://doi.org/10.18632/oncotarget.28242>